The Quality of Life Assessment of Growth Hormone Deficiency in Adults Measure

QHSLab, Inc. Meets the Demand for Updated Mental Health Screening Recommendations from the U.S. Preventive Services Task Force

Retrieved on: 
Tuesday, November 1, 2022
Security (finance), Algorithm, Vital signs, Depressive, WEST, Relaxation, Budget, Sleep, Pain, U.S. Securities and Exchange Commission, Health, The Quality of Life Assessment of Growth Hormone Deficiency in Adults Measure, Assessment, OTCQB, Efficiency, Patient Health Questionnaire, Exercise, GLOBE, Patient, Risk, Physician, GAD, Anxiety disorder, USPSTF, Anxiety, Education, Digital, Private Securities Litigation Reform Act, PCP, Company, PALM, United, Pediatrics, Medicare, United States Public Health Service, United States Preventive Services Task Force, Ageing, Primary care, Quality of life, Forward-looking statement, PHQ, Digital health, Depression, ALL, Health insurance, Medical device, Medicine, Risk management, Medicaid

WEST PALM BEACH, FL, Nov. 01, 2022 (GLOBE NEWSWIRE) -- QHSLab, Inc. (the “Company”) (OTCQB: USAQ), a company focused on providing clinicians with tools to leverage proactive, value-based healthcare solutions through emerging digital health and point-of-care technologies, validates the growing need for the Q-Scale, or “Quality of Life” Scale, a digital medicine assessment tool for screening patients who may be suffering from mental and emotional health-related issues. A recent report from the U.S. Preventive Services Task Force (USPSTF) recommended that ALL patients under the age of 65, including children and adolescents aged 8 to 18 years, be screened for depression and anxiety in their primary care appointments. USPSTF made some of the following comments: 

Key Points: 
  • The independent, non-partisan group, U.S. Preventive Services Task Force, recommends screenings for depression and anxiety among all patients under the age of 65.
  • Primary Care Physicians and pediatricians are often under-equipped to meet the growing demand for mental health services, and need screening tools to ensure efficiency and proper diagnosis.
  • QHSLab, Inc. provides primary care physicians (PCPs) and pediatricians with the digital tools to meet these proposed national mental health guidelines.
  • They are often the first resource seen by patients presenting a mental health concern and can uncover an undiagnosed mental health condition.

Horizon Therapeutics plc Launches Letter-Writing Campaign to Empower Those Living with Thyroid Eye Disease (TED) to Confront the Condition Head On

Retrieved on: 
Wednesday, May 11, 2022
Mental Health, Health, General Health, Pharmaceutical, Optical, Biotechnology, Lazarus, The Quality of Life Assessment of Growth Hormone Deficiency in Adults Measure, Exophthalmos, Lists of World Heritage Sites, Instagram, Twitter, Nasdaq, Fibroblast, Autoimmunity, Courage, Red, Depression, Grave, Thyroid disease, Hypothyroidism, Patient, Mental Health Awareness Month, TED, Letter, Severe cognitive impairment, Family, Hyperthyroidism, Anxiety, Cell, Epidemiology, Television, Health, Conditional sentence, Quality of life, LinkedIn, Graves' ophthalmopathy, Disease, Friends, Science, Autoantibody, European Group, Diplopia, Inflammation, Walking, Strabismus, TED (conference), Paced Auditory Serial Addition Test, American, Risk, Multimedia, Pharmaceutical industry, Health insurance, Vaccine, Silviculture, Atlantic Ocean, Facebook, The New York Times

Living with a rare or chronic disease is a very personal experience that can sometimes feel isolating and overwhelming, said Gottlieb.

Key Points: 
  • Living with a rare or chronic disease is a very personal experience that can sometimes feel isolating and overwhelming, said Gottlieb.
  • My relationship with TED hasnt been easy, but because of what Ive been through, I take pride in everything Ive accomplished.
  • It is important to monitor eye symptoms and take weekly pictures to capture any changes in appearance.
  • Cockerham K, Stuertz N, Padnick-Silver L. Quality of Life Assessment of Chronic Thyroid Eye Disease (TED) Patients in the United States.

Wellness Expert Lindora Launches Hormone Replacement Therapy

Retrieved on: 
Monday, May 9, 2022
Health, Consumer, Women, Other Health, Men, Pharmaceutical, Biotechnology, Board, Functional medicine, Lindora, University, HRT, Medical degree, Woman, Public health, Man, The Quality of Life Assessment of Growth Hormone Deficiency in Adults Measure, Fatigue, Medicine, International Menopause Society, Hormone replacement therapy, Patient, Cryotherapy, Association, Habit, Alternative, Drexel University, Lehigh University, Anxiety, Elective surgery, Weight gain, MD, Libido, Insomnia, Anti-aging movement, American Academy, Weight loss, Fellow, Program, Pharmaceutical industry, Biology, Regeneration, Family medicine

In a move to further expand valuable services to its patient base, Lindora Wellness, Inc. announced today that it will begin to offer Hormone Replacement Therapy (HRT).

Key Points: 
  • In a move to further expand valuable services to its patient base, Lindora Wellness, Inc. announced today that it will begin to offer Hormone Replacement Therapy (HRT).
  • Lindoras HRT Program will be led by Dr. Martha Wittenberg, MD who has been practicing Hormone Replacement Therapy since 2015.
  • Hormone replacement therapy can help to address these symptoms and restore hormone levels to where they were when patients were younger, said Dr. Wittenberg.
  • Lindora, who operates 33 medically based weight loss and wellness clinics in Southern California, has been a leader in weight loss and wellness for more than five decades.

Health And Wellness And Age Management Expert A New You Wellness Joins Exclusive Haute Beauty Network

Retrieved on: 
Thursday, March 17, 2022
The Quality of Life Assessment of Growth Hormone Deficiency in Adults Measure, Family, Naturopathy, Emergency department, Internal medicine, Orphanage, Late-onset hypogonadism, Intensive care unit, Alzheimer's disease, Hospital medicine, Nutrition, Hospital, Menopause, Reading, Cancer, Age, Medical director, Medical degree, University, Food, Hobby, Nursing home, Nutritional science, Haute Living, Beauty, Weight loss, Patient, Bachelor of Science in Human Biology, Medicine, Fashion

His areas of interest and expertise include Nutrition, Naturopathic Medicine, Age Management, Hormone Deficiencies, and Restorative Medicine.

Key Points: 
  • His areas of interest and expertise include Nutrition, Naturopathic Medicine, Age Management, Hormone Deficiencies, and Restorative Medicine.
  • Also, he obtained a board certification in age management medicine with AMMG (Age Management Medicine Group) and continues to thrive and learn more in the area of medical health science.
  • As a section of Haute Living magazine, Haute Beauty covers the latest advancements in beauty and wellness, providing readers with expert advice on aesthetic and reconstructive treatments through its network of acclaimed doctors and beauty experts.
  • For more about Haute Beauty, visit https://hauteliving.com/hautebeauty/
    Brooke Klaiman, Haute Beauty by Haute Living, 5612122126, [email protected]

$16+ Billion Worldwide Drugs For Hormonal Replacement Therapy Industry to 2030 - Identify Growth Segments for Investment - ResearchAndMarkets.com

Retrieved on: 
Thursday, November 11, 2021
General Health, Pharmaceutical, Health, Benchmark, Menopause, Population, Nausea, Hormone, Pharmacy, HGH, Female, Industry, Vaginal bleeding, European Menopause and Andropause Society, Estradiol (medication), Extrapyramidal system, Ageing, International Menopause Society, Coronavirus, Bloating, Growth, Vagina, Thrombus, Estrogen patch, Personal lubricant, Hypogonadism, The Quality of Life Assessment of Growth Hormone Deficiency in Adults Measure, Kent, Woman, Stomach, Cardiovascular disease, HRT, Novo Nordisk, Create, Hypothyroidism, Breast cancer, Male, EMAS, Osteoporosis, Indigestion, Marketing, Birth control

Increasing occurrence of side effects due to the intake of drugs for hormonal deficiency may hinder growth of drugs for hormonal replacement therapy market.

Key Points: 
  • Increasing occurrence of side effects due to the intake of drugs for hormonal deficiency may hinder growth of drugs for hormonal replacement therapy market.
  • Thus, the increasing side effects of drugs hinders the growth of drugs for hormonal replacement therapy.
  • Increasing population of aging and postmenopausal women is driving the drugs for hormonal replacement therapy market growth.
  • Thus, growing women population suffering from menopausal symptoms and aging population drives the market for hormonal replacement therapy drugs market.

Seno Medical Launches CONFIDENCE Registry Study for Imagio® Breast Imaging System

Retrieved on: 
Thursday, October 21, 2021
Stavros S Niarchos, Quality, Technology, Cancer, Certification, Patient, The Quality of Life Assessment of Growth Hormone Deficiency in Adults Measure, Breast, Biopsy, Google Images, VP, Malignancy, Adult, Use, Seno, Quality of life, X-ray, Radiology, Artificial intelligence, GLOBE, PET/CT, Physician, Medical imaging

San Antonio, TX, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Texas-based Seno Medical Instruments, Inc. (Seno) has launched its CONFIDENCE registry to evaluate the efficacy of imaging with opto-acoustic/ultrasound (OA/US) to diagnose breast abnormalities including cancer using its groundbreaking Imagio Breast Imaging System.

Key Points: 
  • San Antonio, TX, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Texas-based Seno Medical Instruments, Inc. (Seno) has launched its CONFIDENCE registry to evaluate the efficacy of imaging with opto-acoustic/ultrasound (OA/US) to diagnose breast abnormalities including cancer using its groundbreaking Imagio Breast Imaging System.
  • The companys OA/US technology combines laser optics and grayscale ultrasound to provide fused functional and anatomical breast imaging.
  • Seno Medical Instruments, Inc. is a San Antonio, Texas-based medical imaging company committed to the development and commercialization of a new modality in cancer diagnosis: opto-acoustic imaging.
  • Approved by the US FDA in January 2021, Seno Medicals Imagio Breast Imaging System fuses opto-acoustic technology with ultrasound (OA/US) to generate real-time functional and anatomical images of the breast.

US FDA Accepts Regulatory Submission from Pfizer and OPKO for Review of Somatrogon to Treat Pediatric Patients with Growth Hormone Deficiency

Retrieved on: 
Monday, January 4, 2021
Health, FDA, Genetics, Other Health, Clinical trials, Pharmaceutical, Biotechnology, Endocrine system, Organ systems, Growth hormones, Branches of biology, Growth hormone therapy, Growth hormone, Transgender hormone therapy, Hypopituitarism, The Quality of Life Assessment of Growth Hormone Deficiency in Adults Measure, the Study, Somatrogon, Growth Hormone Deficiency, GENOTROPIN® (somatropin), OPKO Health, Inc.

In 2014, Pfizer and OPKO entered into a worldwide agreement for the development and commercialization of somatrogon for the treatment of GHD.

Key Points: 
  • In 2014, Pfizer and OPKO entered into a worldwide agreement for the development and commercialization of somatrogon for the treatment of GHD.
  • Somatrogon has received Orphan Drug designation in the U.S. and the EU for the treatment of children and adults with growth hormone deficiency.
  • Growth hormone deficiency is a rare disease characterized by the inadequate secretion of growth hormone from the pituitary gland and affects one in approximately 4,000 to 10,000 people.
  • Patients treated with growth hormone should be checked regularly if they are receiving standard hormone replacement therapy to treat a lack of more than one hormone.

Global Human Growth Hormones Deficiency Drugs Market, 2018-2023 Featuring Ascendis Pharma A/S, Novo Nordisk A/S, Versartis Inc., Opko Health Inc., Pfizer Inc.

Retrieved on: 
Tuesday, May 15, 2018
Endocrine system, Growth hormones, Medicine, Biology, Growth hormone therapy, Growth hormone, GHD, Hormone, Pralmorelin, The Quality of Life Assessment of Growth Hormone Deficiency in Adults Measure

Global Human Growth Hormones Deficiency (GHD) Drugs Market Assessment: Current Market, Pipeline Review, Clinical Trials, Market Potential - Forecast to 2023 also analyzes the overall sizing, growth and forecast of Growth Hormone Deficiency Drugs Market for the global market.

Key Points: 
  • Global Human Growth Hormones Deficiency (GHD) Drugs Market Assessment: Current Market, Pipeline Review, Clinical Trials, Market Potential - Forecast to 2023 also analyzes the overall sizing, growth and forecast of Growth Hormone Deficiency Drugs Market for the global market.
  • The report presents the market potential of four major pipeline drugs (TransCon-hGH, Somapacitan, Somavaratan, Somatrogonmeant) for the treatment of human Growth Hormone Deficiency (GHD).
  • Over the recent years, the human Growth Hormone Deficiency Drugs market is growing rapidly due to rising prevalence of patients with Growth Hormone Deficiency (GHD) around the world.
  • Globally, the growth of human Growth Hormone Deficiency Drugs market is driven by increased penetration of drugs by market players coupled with introduction of new drugs with improved patient compliance.